Renwick Dobson

Dr. Renwick Dobson

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Immunity
Verified
Journal Article
Closed access
JMJames M. Murphy
James M. Murphy
PCPeter E. Czabotar
Peter E. Czabotar
JHJoanne M. Hildebrand
Joanne M. Hildebrand
ILIsabelle S. Lucet
Isabelle S. Lucet
JZJian-Guo Zhang
Jian-Guo Zhang
WAWarren S. Alexander
Warren S. Alexander

6 October 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JHJoanne M. Hildebrand
Joanne M. Hildebrand
MTMaria C. Tanzer
Maria C. Tanzer
ILIsabelle S. Lucet
Isabelle S. Lucet
SYSamuel N. Young
Samuel N. Young
SSSukhdeep K. Spall
Sukhdeep K. Spall
JSJohn Silke
John Silke
Significance: The four-helix bundle (4HB) domain of Mixed Lineage Kinase Domain-Like (MLKL) bears two clusters of residues that are required for cell death by necroptosis. Mutations within a cluster centered on the α4 helix of the 4HB domain of MLKL prevented its membrane translocation, oligomerization, and ability to induce necroptosis. This cluster is composed principally of acidic residues and therefore challenges the idea that the 4HB domain engages negatively charged phospholipid membranes via a conventional positively charged interaction surface. The importance of membrane translocation to MLKL-mediated death is supported by our identification of a small molecule that binds the MLKL pseudokinase domain and retards membrane translocation to inhibit necroptotic signaling.

8 April 2022 in Microbial Biotechnology
Verified
Journal Article
Open access
AHAimee R. Harper
Aimee R. Harper
RDRenwick Dobson
Renwick Dobson
VMVanessa K. Morris
Vanessa K. Morris
GMGert‐Jan Moggré
Gert‐Jan Moggré
Summary: Ethical, environmental and health concerns around dairy products are driving a fast‐growing industry for plant‐based dairy alternatives, but undesirable flavours and textures in available products are limiting their uptake into the mainstream. The molecular processes initiated during fermentation by lactic acid bacteria in dairy products is well understood, such as proteolysis of caseins into peptides and amino acids, and the utilisation of carbohydrates to form lactic acid and exopolysaccharides. These processes are fundamental to developing the flavour and texture of fermented dairy products like cheese and yoghurt, yet how these processes work in plant‐based alternatives is poorly understood. With this knowledge, bespoke fermentative processes could be engineered for specific food qualities in plant‐based foods. This review will provide an overview of recent research that reveals how fermentation occurs in plant‐based milk, with a focus on how differences in plant proteins and carbohydrate structure affect how they undergo the fermentation process. The practical aspects of how this knowledge has been used to develop plant‐based cheeses and yoghurts is also discussed.

27 June 2017 in EMBO Reports
Verified
Journal Article
Open access
PDF file
VRVladimir Rogov
Vladimir Rogov
SAStolz Alexandra
Stolz Alexandra
ARArvind C Ravichandran
Arvind C Ravichandran
DRDiana O Rios‐Szwed
Diana O Rios‐Szwed
HSHironori Suzuki
Hironori Suzuki
DMDavid G McEwan
David G McEwan
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 July 2012 in Biophysical Journal
Verified
Journal Article
Closed access
DMDavide Mercadante
Davide Mercadante
LMLaurence D. Melton
Laurence D. Melton
GNGillian E. Norris
Gillian E. Norris
TLTrevor S. Loo
Trevor S. Loo
MWMartin A.K. Williams
Martin A.K. Williams
GJGeoffrey Jameson
Geoffrey Jameson

27 February 2018 in Antibiotics
Verified
Journal Article
Open access
PDF file
MLMichael Love
Michael Love
DBDinesh Bhandari
Dinesh Bhandari
RDRenwick Dobson
Renwick Dobson
CBCraig Billington
Craig Billington
There is growing concern about the emergence of bacterial strains showing resistance to all classes of antibiotics commonly used in human medicine. Despite the broad range of available antibiotics, bacterial resistance has been identified for every antimicrobial drug developed to date. Alarmingly, there is also an increasing prevalence of multidrug-resistant bacterial strains, rendering some patients effectively untreatable. Therefore, there is an urgent need to develop alternatives to conventional antibiotics for use in the treatment of both humans and food-producing animals. Bacteriophage-encoded lytic enzymes (endolysins), which degrade the cell wall of the bacterial host to release progeny virions, are potential alternatives to antibiotics. Preliminary studies show that endolysins can disrupt the cell wall when applied exogenously, though this has so far proven more effective in Gram-positive bacteria compared with Gram-negative bacteria. Their potential for development is furthered by the prospect of bioengineering, and aided by the modular domain structure of many endolysins, which separates the binding and catalytic activities into distinct subunits. These subunits can be rearranged to create novel, chimeric enzymes with optimized functionality. Furthermore, there is evidence that the development of resistance to these enzymes may be more difficult compared with conventional antibiotics due to their targeting of highly conserved bonds.